1. A stable pharmaceutically acceptable salt of noribogaine insolvate. 2. A stable salt of noribogaine insolvate according to claim 1, characterized in that said salt is a hydrochloride salt. The salt of claim 2, which is a crystalline salt. The crystalline salt according to claim 3, characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from peaks at 11.6 °, 12.1 °, 13.5 °, 13.9 °, 14.9 ° , 15.7 °, 17.1, 17.9 °, 18.3 °, 19.8 °, 20.8 °, 21.0 °, 21.9 °, 22.8 °, 23.3 °, 24.9 °, 25.9 °, 26.4, 29.3 ° and 29.8 ° 2θ (in each case ± 0.2 ° 2θ) .5. The crystalline salt according to claim 3, for which, in the thermogram of differential scanning calorimetry, essentially no temperature transitions are observed at a temperature below 300 ° C. The crystalline salt according to claim 3, for which, in the thermogram of thermogravimetric analysis, there is essentially no mass loss at a temperature below 300 ° C. The crystalline salt of the ansolvate according to claim 3, which has a density exceeding the density of the solvated crystalline hydrochloride salt of noribogaine by at least 3 to 20% .8. The crystalline insolvate salt according to claim 3, which has a unit cell volume of less than about 1800 cubic angstroms, or less than about 1750 cubic angstroms, or less than (1700 ± 2)% cubic angstroms. Crystalline solvated polymorph of noribogaine hydrochloride, characterized in the differential scanning calorimetry thermogram by a mass loss of about 4% at temperatures below 125 ° C. 10. The crystalline solvated polymorph of claim 9, characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from peaks at 9.7, 10.2, 12.0, 13.3, 13.71. Стабильная фармацевтически приемлемая соль ансольвата норибогаина.2. Стабильная соль ансольвата норибогаина по п. 1, отличающаяся тем, что указанная соль представляет собой гидрохлоридную соль.3. Соль по п. 2, представляющая собой кристаллическую соль.4. Кристаллическая соль по п. 3, характеризую
